| Releases One-Stop Service that Reduces Costs and Time Required for the Entire Anticancer Drug Development Process
| Expecting a Substantial Rise in the Development Success Rate
On the 21st, JNPMEDI (CEO, Kwunho Jeong), a clinical data platform company and MediRama (CEO, Hanlim Moon), a strategic consulting company specialized in anticancer drug development, announced the launch of a comprehensive service designed to accelerate success throughout the entire process of anticancer drug development via strategic alliance.
This service is the result of first collaboration after the ‘Anticancer Drug Development Business Agreement’ between the two companies. It was developed by combining MediRama’s clinical development consulting platform, ABCD (Advanced Business model for Clinical Development) and JNPMEDI’s clinical trial data platform, ‘Maven Clinical Cloud’. This integration aims to provide clients with a one-stop service that supports the complex process of anticancer drug development.
MediRama's ABCD Platform provides consulting services, covering the entire spectrum of clinical development, from initial planning to joint development and commercialization. Specifically, leveraging a high level of expertise in anticancer drug clinical development, the platform leads in formulating clinical development strategies, regulatory compliance, and clinical operations.
JNPMEDI's 'Maven Clinical Cloud' maximizes productivity through effective clinical trial data management and technology that enables decentralized clinical trials. Together, the services provided by the two companies offers an optimized solutions for the anticancer drug development process.
With this one-stop service, clients will benefit from protocols development, professional clinical trial operation, and effective clinical data management, all based on the global sized clinical development strategy. This is expected to dramatically reduce the costs and time required for anticancer drug development, while greatly enhancing the likelihood of success.
The CEO of JNPMEDI, Kwunho Jeong stated, “We are looking forward to a synergistic effect from merging our expertise and technological capabilities to maximize the success of a drug development. We believe that this will bring a groundbreaking changes to the field of anticancer drug development, especially known for a low success rate.”
Hanlim Moon, the CEO of MediRama remarked, “We plan to respond to our customers without any delay and support their success. We aspire to be a navigator for companies that are targeting global anticancer drugs by sharing our expertise and deep understanding of the clinical development process, thus providing a shortcut to drug development.”
| Releases One-Stop Service that Reduces Costs and Time Required for the Entire Anticancer Drug Development Process
| Expecting a Substantial Rise in the Development Success Rate
On the 21st, JNPMEDI (CEO, Kwunho Jeong), a clinical data platform company and MediRama (CEO, Hanlim Moon), a strategic consulting company specialized in anticancer drug development, announced the launch of a comprehensive service designed to accelerate success throughout the entire process of anticancer drug development via strategic alliance.
This service is the result of first collaboration after the ‘Anticancer Drug Development Business Agreement’ between the two companies. It was developed by combining MediRama’s clinical development consulting platform, ABCD (Advanced Business model for Clinical Development) and JNPMEDI’s clinical trial data platform, ‘Maven Clinical Cloud’. This integration aims to provide clients with a one-stop service that supports the complex process of anticancer drug development.
MediRama's ABCD Platform provides consulting services, covering the entire spectrum of clinical development, from initial planning to joint development and commercialization. Specifically, leveraging a high level of expertise in anticancer drug clinical development, the platform leads in formulating clinical development strategies, regulatory compliance, and clinical operations.
JNPMEDI's 'Maven Clinical Cloud' maximizes productivity through effective clinical trial data management and technology that enables decentralized clinical trials. Together, the services provided by the two companies offers an optimized solutions for the anticancer drug development process.
With this one-stop service, clients will benefit from protocols development, professional clinical trial operation, and effective clinical data management, all based on the global sized clinical development strategy. This is expected to dramatically reduce the costs and time required for anticancer drug development, while greatly enhancing the likelihood of success.
The CEO of JNPMEDI, Kwunho Jeong stated, “We are looking forward to a synergistic effect from merging our expertise and technological capabilities to maximize the success of a drug development. We believe that this will bring a groundbreaking changes to the field of anticancer drug development, especially known for a low success rate.”
Hanlim Moon, the CEO of MediRama remarked, “We plan to respond to our customers without any delay and support their success. We aspire to be a navigator for companies that are targeting global anticancer drugs by sharing our expertise and deep understanding of the clinical development process, thus providing a shortcut to drug development.”